Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

被引：0
|
作者：
Peter Nash
Iain B. McInnes
Philip J. Mease
Howard Thom
Matthias Hunger
Andreas Karabis
Kunal Gandhi
Shephard Mpofu
Steffen M. Jugl
机构：
[1] University of Queensland,
[2] University of Glasgow,undefined
[3] Swedish Medical Center and University of Washington,undefined
[4] University of Bristol,undefined
[5] MAPI Group,undefined
[6] MAPI Group,undefined
[7] Novartis Pharmaceuticals Corporation,undefined
[8] Novartis Pharma AG,undefined
来源：
Rheumatology and Therapy | 2018年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Under Methods section, heading Analyses: Pairwise Comparisons, one of the probability value was published incorrectly in a sentence. The correct sentence should read as follows.
引用
收藏
页码：595 / 595
相关论文
共 50 条
  • [1] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Peter Nash
    Iain B. McInnes
    Philip J. Mease
    Howard Thom
    Matthias Hunger
    Andreas Karabis
    Kunal Gandhi
    Shephard Mpofu
    Steffen M. Jugl
    [J]. Rheumatology and Therapy, 2018, 5 : 99 - 122
  • [2] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    [J]. RHEUMATOLOGY AND THERAPY, 2018, 5 (01) : 99 - 122
  • [3] SECUKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS RESULTS VERSUS ADALIMUMAB UP TO 48 WEEKS USING A MATCHING-ADJUSTED INDIRECT COMPARISON
    Nash, P.
    McInnes, I. B.
    Mease, P.
    Thom, H.
    Cure, S.
    Palaka, E.
    Gandhi, K.
    Mpofu, S.
    Jugl, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 353 - 354
  • [4] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Adalimumab Using a Matching-Adjusted Indirect Comparison
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Choy, Ernest H.
    Thom, Howard
    Kalyvas, Chrysostomos
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Betts, Keith A.
    Mittal, Manish
    Song, Jinlin
    Skup, Martha
    Joshi, Avani
    [J]. RHEUMATOLOGY AND THERAPY, 2017, 4 (02) : 349 - 362
  • [6] Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
    Vibeke Strand
    Keith A. Betts
    Manish Mittal
    Jinlin Song
    Martha Skup
    Avani Joshi
    [J]. Rheumatology and Therapy, 2017, 4 : 349 - 362
  • [7] Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison (vol 5, pg 99, 2018)
    Nash, Peter
    McInnes, Iain B.
    Mease, Philip J.
    Thom, Howard
    Hunger, Matthias
    Karabis, Andreas
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen M.
    [J]. RHEUMATOLOGY AND THERAPY, 2018, 5 (02) : 595 - 595
  • [8] SECUKINUMAB PROVIDES HIGHER SYMPTOMATIC IMPROVEMENT VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS: COMPARATIVE EFFECTIVENESS UP TO 48 WEEKS ASSESSED BY TWO MATCHING-ADJUSTED INDIRECT COMPARISONS
    Thom, H.
    Hunger, M.
    Rosal, G. F.
    Gandhi, K.
    Jugl, S. M.
    Nash, P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A935 - A935
  • [9] Secukinumab for the Treatment of Psoriatic Arthritis: Comparative Effectiveness Versus Infliximab Using a Matching-Adjusted Indirect Comparison
    Strand, Vibeke
    Mease, Philip J.
    McInnes, Iain B.
    Nash, Peter
    Thom, Howard
    Hunger, Matthias
    Gandhi, Kunal
    Mpofu, Shephard
    Jugl, Steffen
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison
    Mease, Philip J.
    Warren, Richard B.
    Nash, Peter
    Grouin, Jean-Marie
    Lyris, Nikos
    Willems, Damon
    Taieb, Vanessa
    Eells, Jason
    Mcinnes, Iain B.
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (03) : 817 - 828
12345